8-K - Oramed Pharmaceuticals Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Other Event

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry Into a Material Definitive Agreement. Share Purchase Agreement On January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certai

Material Agreement

$200.0M

Source Document

8.01

Other Events. On January 13, 2026, the Company issued a press release announcing the Notes Private Placement and Share Purchase Transaction. A copy of the press

Other Event

9.01

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Share Purchase Warrant. 4.3 Form of Senior Se

Exhibits Only

Source Document

Exhibits (10)

10.1

SHARE PURCHASE AGREEMENT, DATED AS OF JANUARY 12, 2026, BY AND AMONG ORAMED PHARMACEUTICALS INC., ORATECH PHARMA, INC. AND LIFEWARD LTD

10.2

FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF JANUARY 12, 2026

10.3

FORM OF LOCK-UP AGREEMENT, DATED AS OF JANUARY 12, 2026

10.4

FORM OF CLINICAL TRIAL MANAGEMENT AGREEMENT

4.1

FORM OF PRE-FUNDED WARRANT

4.2

FORM OF SHARE PURCHASE WARRANT

4.3

FORM OF SENIOR SECURED CONVERTIBLE NOTE

4.4

FORM OF PURCHASE AGREEMENT WARRANT

8-K

CURRENT REPORT

99.1

PRESS RELEASE DATED JANUARY 13, 2026